Drugs / AD109
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05071612 | Nov 2021 → Jul 2022 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 2 | NCT04580394 | Oct 2020 → May 2021 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05811247 | Aug 2023 → May 2025 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06400615 Comparator | May → Dec 2024 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06400615 ↗ |
| Known as | Aroxybutynin/Atomoxetine | “Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109)” NCT06400615 ↗ |
| Route | Oral | “Oral administration before bed” NCT04580394 ↗ |